<p>Notes: Final model specification: estimated cumulative insulin dose, therapy (±metformin), HbA1c, BMI, diabetes duration, index year, insulin regimen, smoking status, serum creatinine, prior cancer, prior large vessel disease, prior lipid-lowering therapy, prior anti-hypertensive therapy, prior anti-platelet therapy, prior GP contacts, Charlson comorbidity index, gender, and age at index. Insulin dose (units/kg/day) was added as a cumulative dose as an annually updated, time-dependent covariate. Baseline values were used for the remaining covariates as defined in the Statistical Methods section. Prior anti-hypertensive therapy and history of cancer violated the proportional hazards assumption of the Cox model and so were added as Heavisi...
Aims: The objective of this nationwide study was to compare the risk of all-cause mortality, fatal a...
OBJECTIVES The benefits and harms of diabetes treatments need to be carefully weighed in people wit...
<p>Referent group: never-users of metformin; HR: hazard ratio, CI: confidence interval.</p><p>Models...
<p>Blue = insulin monotherapy, green = insulin plus metformin. Time zero refers to index date plus 1...
<p>For the overall model, there was evidence that the proportional hazards assumption was violated f...
<p>Model 1: adjustment for gender and also stratification by quartiles of age in order to avoid viol...
AIMS:To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (MACE)...
<p>Model 1: Crude HR, without adjustment for covariates. Model 2: Adjustment for age, sex, diabetes ...
<p>Adjusted multivariate Cox proportional hazards model for diabetes progression measured as risk of...
<p>Hazard ratios and their 95% CIs were obtained from Cox proportional hazards models adjusted for g...
a<p>Although not shown here, the model also included age at first insulin prescription (FIP), gender...
Aims To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
OBJECTIVE: In the ACCORD trial, intensive treatment of patients with type 2 diabetes and high cardio...
Aims To evaluate the association between insulin exposure and all-cause mortality, incident major a...
Aims: The objective of this nationwide study was to compare the risk of all-cause mortality, fatal a...
OBJECTIVES The benefits and harms of diabetes treatments need to be carefully weighed in people wit...
<p>Referent group: never-users of metformin; HR: hazard ratio, CI: confidence interval.</p><p>Models...
<p>Blue = insulin monotherapy, green = insulin plus metformin. Time zero refers to index date plus 1...
<p>For the overall model, there was evidence that the proportional hazards assumption was violated f...
<p>Model 1: adjustment for gender and also stratification by quartiles of age in order to avoid viol...
AIMS:To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (MACE)...
<p>Model 1: Crude HR, without adjustment for covariates. Model 2: Adjustment for age, sex, diabetes ...
<p>Adjusted multivariate Cox proportional hazards model for diabetes progression measured as risk of...
<p>Hazard ratios and their 95% CIs were obtained from Cox proportional hazards models adjusted for g...
a<p>Although not shown here, the model also included age at first insulin prescription (FIP), gender...
Aims To determine if concomitant metformin reduced the risk of death, major adverse cardiac events (...
OBJECTIVE: In the ACCORD trial, intensive treatment of patients with type 2 diabetes and high cardio...
Aims To evaluate the association between insulin exposure and all-cause mortality, incident major a...
Aims: The objective of this nationwide study was to compare the risk of all-cause mortality, fatal a...
OBJECTIVES The benefits and harms of diabetes treatments need to be carefully weighed in people wit...
<p>Referent group: never-users of metformin; HR: hazard ratio, CI: confidence interval.</p><p>Models...